恩杂鲁胺耐药前列腺癌对超生理剂量睾酮的持久应答与患者来源异种移植瘤中多层面生长抑制及DNA损伤应答转录组程序受损相关
本研究利用13例去势抵抗性前列腺癌患者来源异种移植瘤(PDX)开展临床前试验,其中3例对恩杂鲁胺耐药者接受环丙酸睾酮治疗。鉴定出一例持久应答者,表现为ARv7和E2F转录输出及DNA损伤应答转录组程序持续抑制,上述抑制在短暂应答者发生SPT耐药后恢复;SPT复发PDX再挑战恩杂鲁胺后PSA下降但肿瘤进展。
要点
- 在恩杂鲁胺耐药CRPC的PDX中,超生理剂量睾酮可产生持久应答。
- 持久应答伴随ARv7、E2F转录输出及DNA损伤应答转录组程序的持续抑制。
- SPT耐药后上述转录程序恢复;恩杂鲁胺再挑战可使PSA下降但肿瘤仍进展。
核心结论
- 超生理剂量睾酮在AR通路抑制剂恩杂鲁胺耐药的CRPC中产生持久应答,该应答与ARv7和E2F转录输出及DNA损伤应答转录组的持续抑制相关,提示维持抑制这些程序的联合治疗有望驱动对SPT的持久应答。
研究设计与样本
- 患者来源异种移植瘤(PDX)临床前试验,纳入13例CRPC PDX以鉴定与SPT应答相关的分子特征。
- 对3例对新型雄激素受体通路抑制剂恩杂鲁胺耐药的PDX进行瘤内雄激素、肿瘤生长及整合转录组和蛋白分析,以定义SPT应答与耐药。
- 干预为环丙酸睾酮。
主要发现
- 鉴定出一例持久SPT应答者,表现为ARv7和E2F转录输出及DNA损伤应答转录组程序的强烈抑制。
- 在短暂应答者中,上述抑制在发生SPT耐药后全部恢复。
- 对SPT复发PDX再挑战恩杂鲁胺后,PSA下降但肿瘤进展。
关键数值与推荐
- SPT疗效通过PDX生长、前列腺特异性抗原(PSA)变化和生存评估。
- 瘤内雄激素采用质谱分析;全局转录组分析采用RNA测序,并经定量实时聚合酶链反应和免疫组化确认。
- 生存和分子分析分别采用Log-rank检验和Mann-Whitney检验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen deprivation therapy improves the survival of castration-resistant prostate cancer (CRPC) patients, yet ultimately fails with debilitating side effects. Supraphysiological testosterone (SPT)-based therapy produces clinical responses with improved quality of life in a subset of patients. Currently, no information defines a durable response to SPT. OBJECTIVE: To identify key molecular phenotypes underlying SPT response to improve patient selection and guide combination treatment to achieve a durable response. DESIGN, SETTING, AND PARTICIPANTS: A patient-derived xenograft (PDX) preclinical trial was performed with 13 CRPC PDXs to identify molecular features associated with SPT response. Comprehensive intratumoral androgen, tumor growth, and integrated transcriptomic and protein analyses were performed in three PDXs resistant to the newer androgen receptor (AR) pathway inhibitor enzalutamide (ENZ) to define SPT response and resistance. INTERVENTION: Testosterone cypionate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: SPT efficacy was evaluated by PDX growth, prostate-specific antigen (PSA) change, and survival. Intratumoral androgens were analyzed using mass spectrometry. Global transcriptome analysis was performed using RNA sequencing, and confirmed by quantitative real-time polymerase chain reaction and immunohistochemistry. Log-rank and Mann-Whitney tests were used for survival and molecular analyses, respectively. RESULTS AND LIMITATIONS: A durable SPT responder was identified, presenting robust repressions of ARv7 and E2F transcriptional outputs, and a DNA damage response (DDR) transcriptomic program that were altogether restored upon SPT resistance in the transient responder. ENZ rechallenge of SPT-relapsed PDXs resulted in PSA decreases but tumor progression. CONCLUSIONS: SPT produces a durable response in AR-pathway inhibitor ENZ CRPC that is associated with sustained suppression of ARv7 and E2F transcriptional outputs, and the DDR transcriptome, highlighting the potential of combination treatments that maintain suppression of these programs to drive a durable response to SPT. PATIENT SUMMARY: Patients with ENZ-resistant prostate cancer have very limited treatment options. Supraphysiological testosterone presents a prominent option for improved quality of life and a potential durable response in patients with sustained suppression on ARv7/E2F transcriptional outputs and DNA repair program.
引用
- Lam HM, Nguyen HM, Labrecque MP, et al. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. Eur Urol. 2019. PMID: 31227306. doi:10.1016/j.eururo.2019.05.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。